[ad_1]
LEXINGTON, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a frontrunner within the speedy detection of sepsis-causing pathogens, immediately introduced the execution of territory unique distribution agreements in Norway, Finland, and Türkiye. Beneath the phrases of the agreements, T2 Biosystems will promote T2Dx® Devices, together with T2Bacteria®, T2Candida® and T2Resistance® Panels by these distributors.
The execution of those unique distribution agreements additional expands T2 Biosystems’ commercialization. Epidemiology research have proven that Norway and Finland have skilled a rise within the incidence of blood stream infections (BSIs)1,2 whereas Türkiye endures a excessive prevalence of sepsis and a excessive mortality charge inside hospital Intensive Care Models3. The introduction of the T2Dx Instrument and sepsis panels into these nations will permit speedy detection of sepsis-causing pathogens and antibiotic resistance genes, in hours as an alternative of days, enabling clinicians to realize focused remedy, sooner.
“We’re dedicated to increasing our commercialization worldwide and these new distribution agreements present entry to essential markets in Norway, Finland, and Türkiye,” mentioned John Sperzel, Chairman and CEO of T2 Biosystems. “We consider these three nations signify important development potential for our culture-independent speedy diagnostics and look ahead to constructing lasting relationships with our distributors as we work to enhance the standard of look after these sufferers liable to sepsis.”
About T2 Biosystems
T2 Biosystems, a frontrunner within the speedy detection of sepsis-causing pathogens, is devoted to bettering affected person care and decreasing the price of care by serving to clinicians successfully deal with sufferers sooner than ever earlier than. T2 Biosystems’ merchandise embody the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance® Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) know-how. T2 Biosystems has an energetic pipeline of future merchandise, together with the T2Cauris™ Panel, and T2Lyme™ Panel, in addition to extra merchandise for the detection of bacterial and fungal pathogens and related antimicrobial resistance markers, and biothreat pathogens.
Ahead-Trying Statements
This press launch comprises forward-looking statements inside the that means of the Personal Securities Litigation Reform Act of 1995. All statements contained on this press launch that don’t relate to issues of historic reality needs to be thought of forward-looking statements, together with, with out limitation, statements relating to the power of T2’s culture-independent diagnostics to enhance the usual of look after sufferers liable to sepsis and to develop in Norway, Finland and Türkiye, in addition to statements that embody the phrases “anticipate,” “intend,” “plan”, “consider”, “undertaking”, “forecast”, “estimate,” “might,” “ought to,” “anticipate,” and related statements of a future or ahead trying nature. These forward-looking statements are primarily based on administration’s present expectations. These statements are neither guarantees nor ensures, however contain identified and unknown dangers, uncertainties and different essential elements that will trigger precise outcomes, efficiency or achievements to be materially completely different from any future outcomes, efficiency or achievements expressed or implied by the forward-looking statements, together with, however not restricted to, (i) any incapability to (a) understand anticipated advantages from commitments, contracts or merchandise; (b) efficiently execute strategic priorities; (c) deliver merchandise to market; (d) develop product utilization or adoption; (e) acquire buyer testimonials; (f) precisely predict development assumptions; (g) understand anticipated revenues; (h) incur anticipated ranges of working bills; or (i) enhance the variety of high-risk sufferers at buyer services; (ii) failure of early information to foretell eventual outcomes; (iii) failure to make or acquire anticipated FDA filings or clearances inside anticipated time frames or in any respect; or (iv) the elements mentioned beneath Merchandise 1A. “Threat Elements” within the Firm’s Annual Report on Type 10-Okay for the 12 months ended December 31, 2020, filed with the U.S. Securities and Change Fee, or SEC, on March 31, 2021, and different filings the Firm makes with the SEC now and again. These and different essential elements may trigger precise outcomes to vary materially from these indicated by the forward-looking statements made on this press launch. Any such forward-looking statements signify administration’s estimates as of the date of this press launch. Whereas the Firm might elect to replace such forward-looking statements in some unspecified time in the future sooner or later, until required by regulation, it disclaims any obligation to take action, even when subsequent occasions trigger its views to alter. Thus, nobody ought to assume that the Firm’s silence over time signifies that precise occasions are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements shouldn’t be relied upon as representing the Firm’s views as of any date subsequent to the date of this press launch.
Media Contact:
Meagan Dominick, Vault Communications
mdominick@vaultcommunications.com
773-369-4255
Investor Contact:
Philip Journey Taylor, Gilmartin Group
philip@gilmartinIR.com
415-937-5406
1 https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-017-2291-2#Sec15
2 https://pubmed.ncbi.nlm.nih.gov/34546161/
3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901868/
[ad_2]
Source link
